SB2305: Biosimilar Red Tape Elimination Act
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
A bill to improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Plain-language summary
This bill changes the rules for determining when a biosimilar (a cheaper copy of an expensive biologic drug made from living cells) can be used interchangeably with the original drug it copies. Biosimilars must currently go through strict approval steps to prove they work the same way as the original. The bill aims to simplify these approval steps by reducing paperwork and requirements. It affects pharmaceutical companies developing biosimilars and potentially patients who use these drugs. The bill was recently introduced in Congress and has not yet been debated or voted on.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
SB2305: Biosimilar Red Tape Elimination Act
Upcoming hearings & events
Sponsors
Mike Lee
Primary SponsorCo-sponsors (4)
Ben Lujan
Mike Braun
J.D. Vance
Rand Paul